RFS Pharma, LLC Acquisition - Schedule of Purchase Price Consideration (Details) $ in Thousands |
Dec. 31, 2016
USD ($)
|
|---|---|
| Business Combinations [Abstract] | |
| Purchased in-process research and development | $ 184,966 |
| Net book value of tangible assets acquired | (183) |
| Goodwill | 65,195 |
| Deferred tax liability | (65,195) |
| Total purchase price | $ 184,783 |
| X | ||||||||||
- Definition Business Combination Research And Development In Process. No definition available.
|
| X | ||||||||||
- Definition Total remaining unamortized or unaccreted amounts of premiums, discounts, and intangible assets, in years subsequent to the year of acquisition, when the total amounts of remaining discounts, premiums, and intangible assets exceed 30 percent of stockholders' equity. No definition available.
|
| X | ||||||||||
- Definition The amount of financial assets (as defined) recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities). No definition available.
|